NASDAQ · RNAC
Cartesian Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RNAC: Nov 5, 2026
Cartesian Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.02. The reported EPS for the same quarter last year was $-1.38.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.02 | $-0.95 | $-1.13 | 3 |
| Dec 2026 | $-1.14 | $-1.06 | $-1.20 | 3 |
| Mar 2027 | $-1.13 | $-1.09 | $-1.18 | 2 |
| Jun 2027 | $-0.99 | $-0.95 | $-1.02 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Sep 29, 8:49 AM EDTCartesian Reports Positive Phase 2 Retreatment Data For Descartes-08(RTTNews) – Cartesian Therapeutics (RNAC) reported additional Phase 2 retreatment data for investigational Descartes-08 in generalized myasthenia gravis (MG), showing sustained improvements in disease symptoms 12 months after retreatment.
- RTTNews · Sep 29, 8:33 AM EDTCartesian's Descartes-08 Shows Durable Responses In Myasthenia Gravis(RTTNews) – Tuesday, Cartesian Therapeutics (RNAC) reported additional retreatment data for investigational CAR-T therapy Descartes-08 showing sustained improvements in patients with generalized myasthenia gravis (MG).
- Zacks · Jul 1, 3:33 AM EDTNew Strong Sell Stocks for July 1stCZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
- Zacks · Jun 30, 8:00 AM EDTKiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- RTTNews · Jun 12, 11:36 AM EDTWeekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data(RTTNews) – This week, the biotech sector saw a surge of FDA, EU, and China approvals spanning oncology, dermatology, autoimmune and rare disease indications. Strategic acquisitions and licensing deals drove pipeline expansion, while positive clinical readouts in obesity, MASLD,
- RTTNews · Jun 9, 10:44 PM EDTTop Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch(RTTNews) – Tuesday's top biotech gainers include Regentis, which provided an update on its single-step knee repair implant; Eloxx, after getting uplisted to the Nasdaq; Alignment Healthcare, following recent corporate disclosures, including restricted stock unit (RSU) grants to
- RTTNews · Jun 9, 8:35 AM EDTCartesian Enters Licensing Agreement With WestGene(RTTNews) – Cartesian Therapeutics (RNAC) announced a strategic licensing agreement with WestGene Biopharma Co. to advance the development of in vivo chimeric antigen receptor T-cell therapies in autoimmune diseases. Cartesian is partnering with WestGene to conduct a Phase 1 dos
- RTTNews · May 27, 4:31 AM EDTCartesian Secures $150M Financing To Advance Autoimmune Cell Therapy(RTTNews) – Cartesian Therapeutics, Inc. (RNAC) has entered into a credit facility agreement with K2 HealthVentures worth up to $150 million, securing an initial $50 million tranche that extends its cash runway into 2028 and supports preparations for the commercial launch of its
- Zacks · Apr 30, 8:30 AM EDTCartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue EstimatesCartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of -73.81% and -81.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 20, 7:59 AM EDTCartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Fintel · Mar 9, 8:03 PM EDTCantor Fitzgerald Upgrades Cartesian Therapeutics (RNAC)Fintel reports that on March 9, 2026, Cantor Fitzgerald upgraded their outlook for Cartesian Therapeutics (NasdaqGM:RNAC) from Neutral to Overweight. Analyst Price Forecast Suggests 303.82% Upside
- Zacks · Jan 14, 12:00 PM ESTCartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cartesian Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.